Chimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers. CARTs may lose function inside tumors due to persistent antigen engagement. The aims of this study are to develop low-affinity monoclonal antibodies (mAbs) and low-avidity CARTs for HCC and to test the hypothesis that low-avidity CARTs can resist exhaustion and maintain functions in solid tumors, generating durable antitumor effects.

中文翻译：

---

新型低亲和力磷脂酰肌醇蛋白聚糖 3 特异性 CART 可抵抗疲劳并介导针对 HCC 的持久抗肿瘤作用

用于治疗 HCC 和其他实体瘤的嵌合抗原受体工程 T 细胞 (CART) 不如治疗血癌那么有效。由于持续的抗原结合，CART 可能会在肿瘤内失去功能。本研究的目的是开发针对 HCC 的低亲和力单克隆抗体 (mAb) 和低亲和力 CART，并检验低亲和力 CART 可以抵抗实体瘤衰竭并维持功能，产生持久抗肿瘤作用的假设。